Table 2 Baseline clinical characteristics of the study population

Eosinophil count in peripheral blood

N = 197

Eosinophil count (cells/µL), median [Q1-Q3]

500 [220–750]

 Patients with eos ≥ 300 cells/µL, n/N (%)

143/197 (72.6%)

 Patients with eos ≥ 500 cells/µL, n/N (%)

100/197 (50.8%)

Total serum IgE

N = 144

 IgE level at index date (IU/mL), median [Q1-Q3]

163 [49.8–432]

FeNO

N = 120

FeNO (ppb), median [Q1-Q3]

36.8 [19.2–64]

 FeNO < 25 ppb, n/N (%)

44/120 (36.7%)

 FeNO ≥ 25 ppb < 50 ppb, n/N (%)

30/120 (25.0%)

 FeNO ≥ 50 ppb, n/N (%)

46/120 (38.3%)

Patients with previous biological treatments, n/N (%)^a

63/204 (30.9%)

 1 previous line

57/204 (27.9%)

 2 previous lines

5/204 (2.5%)

 3 previous lines

1/204 (1.6%)

 Omalizumab

32/203 (15.7%)

 Mepolizumab

33/203 (16.3%)

 Reslizumab

5/203 (2.5%)

Other previous asthma treatments, n/N (%)

 LAMA

152/204 (74.5%)

 LTRA

117/204 (57.4%)

Use of OCS

N = 182

OCS-dependent patients, n/N (%)^b

53/182 (29.1%)

 Daily OCS dose (mg), mean (SD)

19.7 (15.8)

 Daily OCS dose (mg), median [Q1-Q3]

 Daily OCS dose > 5 mg/day, n/N (%)

15 [6.9–29.0]

41/53 (77.4%)

Severe exacerbations

N = 204

Patients with severe exacerbations, n/N (%)

173/204 (84.8%)

Severe exacerbations, mean (SD)

2.5 (2.3)

Lung function

N = 170

Pre-BD FEV₁ (mL), mean (SD)

1909 (780)^c

Pre-BD FEV₁ (% predicted), mean (SD)

67.3 (21.0)

Patients with pre-BD FEV₁ ≥ 80%, n/N (%)

50/170 (29.4%)

Asthma control

N = 148

ACT score, mean (SD)

14.1 (5.1)

ACT score ≥ 20, n/N (%)

24/148 (16.2%)